{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
Bernardi S, Marcuzzi A, Piscianz E, Tommasini A, Fabris B. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int J Mol Sci 2018;19(12)\par \par Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, Fabris B. Association between thyroid hormones and TRAIL. Clin Biochem 2017;50(16-17):972-976.\par \par Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, Barbone F, Fabris B. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017;18(1):219.\par \par Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B. TRAIL modulates the immune system and protects against the development of diabetes. J Immunol Res 2015;2015:680749.\par \par Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.\par \par Tisato V, Toffoli B, Monasta L, Bernardi S, Candido R, Zauli G, Secchiero P. Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clin Nutr 2013;32(2):259-64.\par \par Bernardi S, Norcio A, Toffoli B, Zauli G, Secchiero P. Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 2012;18(35):5759-65.\par \par Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.\par \par Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.\par \par Bernardi S, Milani D, Fabris B, Secchiero P, Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.\par \par Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.\par \par Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.\par \par Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, Fabris B, Zauli G, Secchiero P, Thomas MC. Osteoprotegerin promotes vascular fibrosis via a TGF-?1 autocrine loop. Atherosclerosis 2011;218(1):61-8.\par \par }